Since ADAM17 has emerged as a protease that contributes to the pathogenesis of a multitude of disease states, a wide majority of small molecules synthesized so far as selective ADAM17 inhibitors were tested in tumors, chronic inflammatory diseases, and immune disorders [17,109]. The gene discussed is ADAM17; the disease is immune system disorder.